Pyxis Oncology Reports Financial Results for the Quarter Ended September 30, 2022 and Provides Corporate Update
CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS) today reported financial results for the third quarter and nine months ended September 30, 2022 and provided a corporate update.
- Jeff Settleman, Ph.D., Senior Vice President and Chief Scientific Officer for Oncology Research and Development at Pfizer, added, We are proud to strengthen our agreement with Pyxis Oncology.
- Pyxis Oncology has assembled a talented team, and we are confident in their ability to fully realize the platforms clinical potential.
- The amended agreement provides Pyxis Oncology with the flexibility to sublicenseeitherthe full platform or certain components of the platform to third parties.
- As of November 1, 2022, the outstanding number of shares of Common Stock of Pyxis Oncology was 35,097,256.